Skip To Main Content
Barry A. Borlaug on Muck Rack

Barry A. Borlaug

As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, heart, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, JAMA Cardiology, Medscape, The New England Journal of Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry A.

Contact Barry A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Right Ventricular Metrics as End Points in Clinical Trials : A Review

|
By Elena Surkova, Bálint K. Lakatos, Hannah R. Kempton, Alex Lee Verified, JoAnn Lindenfeld, Joao Lima, Stephan Rosenkranz, Barry A. Borlaug, Jörg Hausleiter, Daniel Burkhoff, Denisa Muraru, Martin Leon, Béla Merkely, Rebecca T. Hahn, Attila Kovacs
| JAMA Cardiology
Right Ventricular Metrics as End Points in Clinical Trials: A Review Abstract Importance Clinical trials in cardiovascular medicine aim to deliver high-quality evidence with greater efficiency, including smaller sample sizes and shorter timelines. The selection of sensitive and reliable end points is central to this goal.
Open in Who Shared Issue with article?

Updated HFmrEF Guidelines From HFSA Support Standard HFrEF Treatment

|
By Barry A. Borlaug
| consultantlive.com
The Heart Failure Society of America (HFSA) has released a new scientific statement encouraging the acceptance of heart failure with mildly reduced ejection fraction (HFmrEF) as its own distinct condition.1 Prior to the statement’s release, HFmrEF has largely been considered a gray zone in between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), and as a result has been understudied.
Open in Who Shared View Duplicates (2) Issue with article?

Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP‐HFpEF programme

|
By Ambarish Pandey Verified, Michael Moroney, Subodh Verma, Barry A. Borlaug
| Wiley Online Library Verified
Background Obesity-related heart failure (HF) with preserved ejection fraction (HFpEF) is characterized by worse quality of life, impaired physical function, and high cardiac filling pressures.1-3 Older patients with obesity-related HFpEF have a high burden of sarcopenia and physical dysfunction and are at a higher risk of adverse clinical outcomes.4 Incretin-based weight loss therapies have demonstrated efficacy in improving disease-specific symptoms, physical function, and exercise capacity...
Open in Who Shared Issue with article?
See all 108 licensed articles (117 Total)